Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

This article was originally published in Scrip

Executive Summary

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included the death of a Supreme Court justice, which may have implications for cases affecting the biopharmaceutical industry currently pending before the court or those expected to reach it in the next year or two; the Senate majority leader's move to hold a procedural vote on Feb. 22 in the first step to clear Robert Califf as the new commissioner of the FDA; a complaint by federal health officials and lawmakers that profits appear to drive industry's interest in pursuing vaccines against infectious diseases; and the Senate Health Committee's adoption of seven bills under the panel's "innovation project," which is intended to be a "step-by-step" approach for overhauling the US biomedical enterprise; plus other Washington news.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel